Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™SARS-COV-2 항바이러스 치료제 Paxlovid™의 적시 개발을 지원하는 Nirmatrelvir의 포괄적인 비임상 안전성 평가Article Published on 2022-08-012022-09-11 Journal: International journal of toxicology [Category] 치료제, [키워드] 3CL administration Antiviral Arrhythmias assessment blood pressure cardiovascular caused clinical development Clinical pathology coagulation time Comprehensive conducted COVID-19 COVID-19 patient COVID-19 patients death decrease decreases development dose Drug safety Effect Efficacy Endpoint enhancer enzyme functional heart rate high risk highest dose Hospitalization Increases increases in induce Infection locomotor male MPro nervous system Nirmatrelvir not affect pathology Paxlovid pharmacokinetic Potential produced profile protease RATs Replication respiratory rate Ritonavir Safety safety pharmacology SARS-CoV-2 SARS-CoV-2 virus Support Supporting target tested the SARS-CoV-2 virus toxicities Toxicity toxicology transaminase transaminases Treatment treatment of COVID-19 were assessed [DOI] 10.1177/10915818221095489 PMC 바로가기 [Article Type] Article
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19약물동력학적 부스터와의 약물-약물 상호작용 위험 평가: 중증 COVID-19를 예방하기 위한 리토나비르 강화 니르마트렐비르의 사례Article Published on 2022-08-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] SARS, 진단, 치료제, [키워드] Abstract antivirals COVID-19 drug Drug safety drug-drug interaction Drug-drug interactions Evaluating Nirmatrelvir pharmacokinetic Pharmacokinetic boosters Prevent risk Ritonavir severe COVID-19 [DOI] 10.1016/j.cmi.2022.03.030 PMC 바로가기 [Article Type] Article
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences위험, 약리학 그룹 및 결과에 따라 분류된 Paxlovid 팩트 시트에 나열된 상호 작용Article Published on 2022-08-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] Administered Antiviral consequence COVID-19 CYP3A4 drug Drug interactions ELLA English force groups inhibitor Isoenzyme low dose medication Medicine Medicines metabolism Nirmatrelvir oxidative Paxlovid pharmacological Precaution precautions Prophylaxis protease responsible Ritonavir SARS-CoV-2 SARS-CoV-2 main protease Spanish therapeutic therapeutic effect Treatment [DOI] 10.37201/req/054.2022 PMC 바로가기 [Article Type] Article
Outpatient treatment options to address the SARS-CoV-2 variant OmicronArticle Published on 2022-08-012023-07-09 Journal: Expert review of anti-infective therapy [Category] COVID19(2023년), [키워드] bebtelovimab COVID-19 molnupiravir Nirmatrelvir Outpatient [DOI] 10.1080/14787210.2022.2077191
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis중증이 아닌 COVID-19에 대한 항바이러스제 치료: 체계적인 검토 및 네트워크 메타 분석Meta-Analysis Published on 2022-07-252022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] COVID19(2023년), meta-analysis, SARS, 변종, 치료제, [키워드] 95% CI 95% confidence interval Admission Adult patients antiviral drug antiviral drugs antiviral treatments approach assessment certainty certainty of evidence conducted COVID-19 database death development drug effective Effectiveness Evidence Hospital admission Hospital admissions moderate molnupiravir MOST Network meta-analysis Nirmatrelvir no effect omicron Omicron variant Patient patients patients with COVID-19 performed Placebo randomized trial randomized trials reduce reduced risk reducing Remdesivir risk Risk of bias risk of death Ritonavir searched standard care systematic review tested Treatment Trial trials variants [DOI] 10.1503/cmaj.220471 PMC 바로가기 [Article Type] Meta-Analysis
Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling이중 작용 항바이러스/항염 소분자 및 생리학적 기반 약동학 모델링을 통한 COVID-19에 대한 새로운 치료법 개발Review Published on 2022-07-202022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] (dexamethasone Anti-inflammatory Anti-SARS-CoV-2 Activity Antiviral antiviral agent Antiviral agents approach Baricitinib biochemical pathway Biochemical pathways characterization COVID-19 COVID-19 pandemic Critical Cytopathic effect develop Developing Dexamethasone drug target dual dual action early treatment effective Efficacy and safety health system health systems High-risk patients identify in silico in vitro in vivo model Infection inflammatory cascade inhibitor inhibitors mechanism Mild mild to moderate Mild to moderate COVID-19 modeling Moderate COVID-19 molecular docking molecule molnupiravir monoclonal antibodies multidisciplinary approach New Nirmatrelvir pandemic pathogen PBPK modeling pharmacological protocol Ritonavir therapeutic agent therapeutic agents threat Treatment treatment of COVID-19 Viral virus viruses [DOI] 10.3390/ijms23148006 PMC 바로가기 [Article Type] Review
Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric StudiesSARS-CoV-2 바이러스 제거 동역학 특성화를 통해 항바이러스 약리학적 연구 설계 개선Article Published on 2022-07-192022-09-11 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료제, [키워드] analyzed Antiviral antiviral drug antiviral drugs antiviral effects antiviral treatments assessment clearance clearance rate clinical trials conducted Consensus COVID-19 illness Effect estimate exponential decay model individuals Infection Kinetics methodology Metrics molnupiravir Nasopharyngeal swab Nasopharyngeal swab samples Nirmatrelvir Patient Pharmacodynamics Phase 2 profile provide qPCR randomized trial randomized trials reduced reported robust Sample size sample sizes SARS-CoV-2 splines Statistical power time to clearance. Trial viral clearance Viral load virological response [DOI] 10.1128/aac.00192-22 PMC 바로가기 [Article Type] Article
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of NirmatrelvirNirmatrelvir의 잠재적인 SARS-CoV-2 회피에 대한 진화적 및 구조적 통찰력Review Published on 2022-07-142022-09-11 Journal: Journal of medicinal chemistry [Category] COVID19(2023년), SARS, 변종, [키워드] Analysis analyzed antibody approval arises broad-spectrum antiviral broad-spectrum antivirals combination therapy COVID-19 pandemic drug-resistant indicate inhibitor insight M pro Mutation Nirmatrelvir Paxlovid Potential Pro protease residue residues Ritonavir SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants significantly U.S. FDA Vaccine Viral resistance viral variant [DOI] 10.1021/acs.jmedchem.2c00404 PMC 바로가기 [Article Type] Review
Paxlovid: Mechanism of Action, Synthesis, and In Silico StudyPaxlovid: 작용 메커니즘, 종합 및 인 실리코 연구Review Published on 2022-07-072022-09-11 Journal: BioMed Research International [Category] COVID19(2023년), SARS, 치료제, [키워드] Action antiviral activity antiviral drug antiviral efficacy antivirus antiviruses Biochemistry candidate cleave clinical trial Combination coronavirus COVID COVID-19 COVID-19 pandemic described description drug flexible Glutamine human coronavirus Immune profile in vitro in vivo inhibiting inhibitor mechanism mechanism of action molnupiravir Nirmatrelvir Organic chemistry pandemic Paxlovid PF-07321332 Pfizer Pharmacology polyprotein protease Protease inhibitor Proteases replaced REPLACED BY reported Ritonavir SARS-CoV-2 protease synthesis Treatment treatment of COVID-19 Vaccine viral replication [DOI] 10.1155/2022/7341493 PMC 바로가기 [Article Type] Review
Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity, and possible drug therapeuticsSARS-CoV-2 Omicron 변이체의 컴퓨터 분석에서 얻은 통찰력: 숙주-병원체 상호작용, 병원성 및 가능한 약물 치료법Article Published on 2022-07-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 Affect Alter Analysis analyzed angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 approach binding affinity Characteristics Comparisons computational analysis correlated correlation correlations COVID-19 COVID-19 case COVID-19 cases docking docking result docking results drug Drug efficacy drugs drugs efficacy effective Effectiveness epidemiological evaluate evaluated Factor genomic sequence Host host-pathogen interaction human receptors insight Interaction lack less Lopinavir molecular docking molecular dynamics Molecular dynamics simulation Mutation mutational spectrum Nirmatrelvir NRP1 occurred omicron Omicron variant pathogenic pathogenicity Phylogenetic tree protease Protein Proteins raised Receptor-binding domain reconstructed Research response significant difference significant differences tested the receptor-binding domain the SARS-CoV-2 therapeutic approaches variant [DOI] 10.1002/iid3.639 PMC 바로가기 [Article Type] Article